| 000 | 00991 a2200277 4500 | ||
|---|---|---|---|
| 005 | 20250511185316.0 | ||
| 264 | 0 | _c19930125 | |
| 008 | 199301s 0 0 eng d | ||
| 022 | _a0364-5134 | ||
| 024 | 7 |
_a10.1002/ana.410320614 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSchulzer, M | |
| 245 | 0 | 0 |
_aThe antiparkinson efficacy of deprenyl derives from transient improvement that is likely to be symptomatic. _h[electronic resource] |
| 260 |
_bAnnals of neurology _cDec 1992 |
||
| 300 |
_a795-8 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aModels, Statistical |
| 650 | 0 | 4 |
_aParkinson Disease _xdrug therapy |
| 650 | 0 | 4 |
_aSelegiline _xtherapeutic use |
| 650 | 0 | 4 | _aSurvival Analysis |
| 700 | 1 | _aMak, E | |
| 700 | 1 | _aCalne, D B | |
| 773 | 0 |
_tAnnals of neurology _gvol. 32 _gno. 6 _gp. 795-8 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/ana.410320614 _zAvailable from publisher's website |
| 999 |
_c1478358 _d1478358 |
||